CMIC Holdings and Median Technologies venture into agreement ensuring Clinical Trial Services
Median Technologies, the industry-leading Imaging Phenomics Company and CMIC HOLDINGS Co., Ltd. (CMIC), a leading Contract Research Organization (CRO) with services for development, manufacturing, sales, and marketing of pharmaceutical products, today announced a collaborative agreement for comprehensive clinical trial services. Together, Median and CMIC will leverage complementary expertise to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia.
The agreement came following an onsite audit at Median’s headquarters in France late last year. Through the collaboration, CMIC will access Median’s innovative imaging technologies, services and imaging expertise.
Nicholas Campbell, Chief Commercial Officer at Median Technologies said “We have been accelerating our expansion in Asia with the opening of our subsidiary in Shanghai and recent key new hires in Japan and China. Our CMIC collaboration strengthens our efforts and extends our footprint for our clinical trial business in the fast-growing Asian market. We look forward to a fruitful partnership,” added Campbell.